Challenges in the use of in silico tools for predicting peptides binding to HLA-class II molecules of HCV E1, E2, and P7.

The application of in silico tools for the development of T-cell vaccines is crucial. Yet, due to myriad of polymorphisms of human T-lymphocytic antigen challenges, such therapeutic opportunities present unique roadblocks. There is an obvious advantage in using immunoinformatics (i.